Skip to main content
Fig. 3 | BMC Medical Research Methodology

Fig. 3

From: Incorporating adjustments for variability in control group response rates in network meta-analysis: a case study of biologics for rheumatoid arthritis

Fig. 3

Scatterplot of placebo response rates versus log (OR) for ACR 50 response. A scatterplot of the natural log of each study’s treatment effect against its corresponding control group response rate. Points are color-coded by intervention. A clear relationship exists between % control group response and treatment effect, wherein lower response rates are associated with larger treatment effects. Legend: ABA = abatacept; ADA = adalimumab; BAR_4 = 4 mg baricitinib; CERTO = certolizumab pegol; csDMARD = conventional synthetic disease-modifying anti-rheumatic drug; ETN = etanercept; GOL = golimumab; INF = infliximab; IV = intravenous; MTX = methotrexate; RIT = rituximab; SAR_200 = 200 mg sarilumab; SC = subcutaneous; SSZ = sulfasalazine; STD = standard dose; TOC_4 = tocilizumab 4 mg/kg; TOC_8 = 8 mg/kg tocilizumab; TOF = tofacitinib

Back to article page